Hedge funds cut NFLX, keep big bets on MSFT, AMZN, add NVDA
On Thursday, Morgan Stanley (NYSE:MS) adjusted its outlook on Biohaven Pharmaceutical (TADAWUL:2070) Holding (NYSE:BHVN) shares, reducing the price target from $69.00 to $63.00. Despite the decrease in the price target, the firm maintained its Overweight rating on the stock. According to InvestingPro data, the company maintains a strong balance sheet with cash reserves exceeding debt levels, though it’s currently experiencing rapid cash burn.
The adjustment by Morgan Stanley followed a review of Biohaven’s fourth-quarter performance and recent financial disclosures. The firm’s analysts updated their model for Biohaven, factoring out projected sales of BHV-7000, a Kv7 activator intended for the treatment of bipolar disorder. This decision was made after considering the company’s fourth-quarter expense trends and details from its annual 10-K filing with the SEC. The stock has shown significant volatility recently, with notable declines over the past week and month, as tracked by InvestingPro.
Morgan Stanley’s analysts highlighted that the primary point of interest for Biohaven’s stock is the anticipated decision by the FDA on Troriluzole, a medication being evaluated for the treatment of Spinocerebellar Ataxia (SCA). The firm’s Overweight rating indicates their positive outlook on the stock’s performance. While InvestingPro analysis shows the company isn’t currently profitable, it maintains strong liquidity with liquid assets exceeding short-term obligations. Unlock 10+ additional key insights and detailed financial metrics with InvestingPro’s comprehensive research report.
Biohaven’s focus remains on the FDA’s upcoming action regarding Troriluzole. The company’s efforts in developing this drug are closely watched by investors, as it represents a significant potential product in its pipeline.
Morgan Stanley’s revised price target of $63.00 reflects the updated analysis and expectations for Biohaven’s financial trajectory and product portfolio development. Despite the lowered price target, the Overweight rating suggests that the firm still sees potential for the stock to perform well relative to the market.
In other recent news, Biohaven Pharmaceutical Holding has seen several developments regarding its drug pipeline and analyst ratings. H.C. Wainwright reaffirmed a Buy rating with a $54 price target, following promising Phase 1 study results of Biohaven’s BHV-1300, which demonstrated an 84% reduction in IgG levels. Jefferies, while slightly reducing its price target from $64 to $63, maintained a Buy rating, citing the positive aspects of BHV-1300 despite some concerns about dosing. TD Cowen also reiterated a Buy rating with a $75 price target, highlighting the significant progress of BHV-1300 and its potential in treating Graves’ disease.
Meanwhile, RBC Capital Markets maintained an Outperform rating with a $61 price target, emphasizing the potential of Biohaven’s IgG program and other pipeline projects despite a setback in a bipolar disorder trial. Bernstein adjusted its price target from $73 to $57, retaining an Outperform rating but expressing concerns over recent mixed results and cash needs. Despite these challenges, Bernstein analysts remain optimistic about the long-term potential of Biohaven’s degrader platform and small chain antibody regulatory events. Overall, Biohaven’s recent developments have attracted varied responses from analysts, each highlighting different aspects of the company’s ongoing projects and future potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.